PARIS–(DWPR)–Cure51, a pioneering TechBio company, has launched the Rosalind study in the UK, a transformative initiative aimed at uncovering the biological mechanisms behind exceptional cancer survivor patients. In collaboration with Cambridge University Hospitals and seven other leading UK institutions, the study seeks to decode the biological factors contributing to long-term cancer survival, with the potential to improve treatment outcomes globally.
The Rosalind study focuses on three aggressive cancer types: extensive stage small cell lung cancer, glioblastoma, and metastatic pancreatic ductal adenocarcinoma. Over 1,000 tumor samples from exceptional responders—patients in the top 3% of survival outcomes—will be analyzed for genetics and biomarkers to identify novel therapeutic targets.
“This is a pivotal step in the Rosalind study as we expand to the UK, our first and largest partnership in this region,” said Nicolas Wolikow, CEO and Co-Founder of Cure51. “With the support of eight leading hospitals, we aim to identify what sets cancer survivors apart to unlock new therapeutic possibilities.”
Dr. Thankammah Ajithkummar, Consultant Clinical Oncologist at Cambridge University Hospitals, commented: “Understanding why some patients achieve remarkable survival is critical to advancing cancer treatment. The Rosalind study provides an exciting new lens through which to explore these differences.”
Cure51 recently secured €15 million in Seed funding led by Sofinnova Partners, alongside a partnership with 10xGenomics, to leverage precision technology for transformative cancer research. The study exemplifies Cure51’s commitment to leveraging technology, data, and multi-disciplinary expertise to revolutionize cancer treatments.
About Cure51
Founded in Paris, Cure51 is a TechBio company dedicated to decoding the biological mechanisms behind exceptional cancer survival. Through a unique multiomics database and computational modeling, Cure51 identifies therapeutic targets and collaborates with world-class oncology centers for transformative research. Visit cure51.com for more information.
Contacts
Media Contacts:
Cure 51
Email: [email protected]
United Kingdom:
Optimum Strategic Communications
Hana Malik
Email: [email protected]
Phone: +44 (0) 20 3882 2119
France:
StrategiesImage
Anne Rein
Email: [email protected]
Phone: +33 (0) 6 03 35 92 05
Italy:
Havas PR Milan
Pierluigi Cavarai
Email: [email protected]
Phone: +39 (0) 392 77 999 33